Encouraging real-world evidence presented by researchers at @mayoclinic.org during the @societyofhemonc.bsky.social Annual Meeting! 🩸 #SOHO2026

Late-line use of asciminib demonstrated considerable effectiveness in treating Ph+ALL!

Read more here: https://bit.ly/4r7DdDx

Research from #SOHO2026: The Phase 3 ECHO trial support frontline acalabrutinib + bendamustine–rituximab (ABR) for untreated mantle cell #Lymphoma!

Key takeaways:
• ~6 yrs vs. ~4 yrs median PFS favoring ABR over PBR
• 32% lower risk of progression or death

#SOHO26 🩸

More: https://bit.ly/4iiVXO8

ELVN-001 produced molecular responses in previously treated CP-CML according to updated data from the phase 1 ENABLE trial. @societyofhemonc.bsky.social #leusm #hematology

See our site for the full story, as presented at #SOHO2026! www.onclive.com/view/elvn-00...

#SOHO2026: The addition of ianalumab to eltrombopag therapy provides patients with primary ITP with durable improvements in symptom burden and fatigue that persist even after eltrombopag discontinuation📊🩺

Source: The phase 3 VAYHIT2 trial #SOHO26

Link to article: https://bit.ly/4inSRbO

📈 The ACTIVE regimen yielded responses in heavily pretreated, relapsed or refractory NPM1-mutated AML, according to findings presented at #SOHO2026. @societyofhemonc.bsky.social #leusm #hematology

See the full story from the retrospective study on our site ➡️: www.onclive.com/view/active-...

Adding revumenib to intensive chemotherapy led to high levels of response and MRD negativity in newly diagnosed AML harboring NPM1 mutations or KMT2A rearrangements #leusm #oncology

Check out the phase 1 data from #SOHO2026 www.onclive.com/view/revumen...

New from #SOHO26! CALGB 10403 (C10403) protocol used in adolescents and young adults with acute lymphoblastic leukemia may be equally safe and effective in adults aged 40+!

Read the full article here: https://bit.ly/4yx5upH

#ALL #SOHO2026 #Leukemia

When Killer-T shows up, everybody wants a photo 📸⭐️ Want your moment? Go find him at the photobooth. #SOHO2026

Dr. Elias Jabbour, our superstar editor at SOHO Insider, on the hottest topics in ALL (Acute Lymphoblastic Leukemia) #SOHO2026

Final phase 2 data showed hematologic improvement and durable transfusion independence with ofirnoflast in patients with lower-risk MDS #SOHO2026

Read more: www.onclive.com/view/ofirnof...

Read the new Clinical Hemato-Oncology article collection showcasing Blood Cancer Discovery content on clinical hemato-oncology research and practice, encompassing biology-informed prognostication, new therapies, clinical trials, and post-approval real-life outcomes. buff.ly/LqRwkla #SOHO2026

Treatment with DISC-3405 lowered the rates of phlebotomy after 26 weeks of treatment and maintained hematocrit levels below 45% in patients with polycythemia vera

Dive into data from the phase 2 RESTORE-PV trial presented at #SOHO2026 www.onclive.com/view/disc-34...

❓How did selcodebart perform in anemia-defined cohorts of patients with myelofibrosis?

See our site for the data readout of the RALLY-MF trial presented at #SOHO2026! @societyofhemonc.bsky.social #mpnsm #hematology

www.onclive.com/view/selcode...

September 10 at 1:57 PM Plenary II is coming up, featuring Susan O'Brien, MD of UC Irvine. #SOHO2026

Not in Houston? No problem! Watch all the highlights from #SOHO2026 on the mobile app: buff.ly/ECsYFPJ

New data presented at #SOHO2026 shows promising results for pirtobrutinib in treatment-naïve CLL/SLL! 🔬

📊 93.3% ORR
📈 93.2% 24-month PFS
❤️ 97.5% 24-month OS

Low rate of discontinuation due to treatment-related adverse events (1.6%).
@societyofhemonc.bsky.social

Article: https://bit.ly/4j0oUyu

Phase 2 data show ofirnoflast improves transfusion burden and hemoglobin in low-risk MDS

Presented at #SOHO2026 by Varun Bafna, MD, of UCSF. Read more: buff.ly/pqKIxt5

2️⃣ conferences at once! Get ready for #SOHO2026 in Houston and #WCLC26 in Seoul!
🤠 Over the next few days, we’ll be covering the two conferences in-depth with expert insight all on our site! 🇰🇷
@societyofhemonc.bsky.social @iaslc.bsky.social #lcsm #leusm #mmsm #mpnsm #lymsm #oncology #hematology

The phase 3 DAYBreak CLL-306 study presented at #SOHO2026 shows researchers are investigating the efficacy and safety of bexobrutideg compared with the BTKi pirtobrutinib in patients with CLL/SLL who are relapsed or refractory to prior covalent BTKi treatment.

Full article: https://bit.ly/4A2ECPR

Killer T is ready to meet you! 📸 So great to see Tom Martin from UCSF here at #SOHO2026 come by the photo booth for your own pic with Killer T!

#SOHO2026 Starts TODAY!!🩸

We'll be covering this year's conference live on our website and our social platforms. Click the link below to be brought directly to our conference landing page.

Are there any presentations you're looking forward to at #SOHO26?

🔗 https://bit.ly/4iT6fEO